Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms
Our study findings indicate that OS rate is inferior in patients with relapsed AML or MDS treated with haploidentical DLI in comparison to those who received HLA-identical DLI. Given the limitations of haploidentical DLI, alternative strategies, such as higher cell doses or combination treatment approaches, warrant further investigation.
Authors
- Tobias Matthieu Benoit (ORCID: https://orcid.org/0009-0004-5667-9726)
- Markus Gabriel Manz (ORCID: https://orcid.org/0000-0002-4676-7931)
- Nathan Wolfensberger
- Adrian Bachofner
- Dominik Schneidawind (ORCID: https://orcid.org/0000-0002-2672-431X)
- Yvonne Zaugg‐Berger
Institutions
- University Hospital of Zurich (CH)
- University Children's Hospital Tübingen (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1111/ejh.14340
- Citations
- 2
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.91